Your session is about to expire
← Back to Search
paclitaxel for Thyroid Cancer
Study Summary
This trial will study how well efatutazone dihydrochloride and paclitaxel work in treating patients with advanced anaplastic thyroid cancer.
- Thyroid Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 2 trial • 149 Patients • NCT02004093Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals have enrolled in this experiment?
"This clinical trial has finished enrolling patients. It was initially posted in September 2014 and the last update occurred on August 16th 2021. There are a plethora of other trials actively recruiting; 229 for thyroid cancer, anaplastic, and 833 for paclitaxel specifically."
Have other medical studies explored the efficacy of paclitaxel?
"Currently, 833 medical trials that research paclitaxel are ongoing and 227 of them have reached the 3rd stage. Most trails regarding this drug take place in Melbourne, Victoria yet there is a total of 45766 different sites conducting tests for it."
Does this research offer opportunities for patient involvement?
"At present, this clinical trial is not accepting new participants. As indicated on the clinicaltrials.gov website, it was first posted in September 2014 and most recently updated in August 2021. Fortunately, there are 1062 other studies actively recruiting patients at this time."
Has paclitaxel been granted permission to be used in approved treatments by the FDA?
"Paclitaxel was assigned a score of 2 due to the lack of evidence supporting its efficacy, though there is data indicating it has some safety."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger